
    
      Prospective, randomized multi-center, open label phase II study to determine the activity of
      a non-chemotherapy first line biological treatment with Erlotinib/Bevacizumab or
      Gemcitabine-Cisplatin/Bevacizumab in patients with the diagnosis of non-squamous advanced
      Non-Small-Lung-Cancer.

        -  Duration of treatment/patient: up to 1,5 years

        -  Follow Up: â‰ˆ 6 month

        -  Planned number of patients: 220 treated patients (110 patients/arm)
    
  